|1.||Kirsch, David G: 5 articles (09/2015 - 05/2012)|
|2.||Grisham, Matthew B: 5 articles (03/2011 - 02/2006)|
|3.||Moding, Everett J: 4 articles (03/2015 - 05/2012)|
|4.||Lee, Chang-Lung: 4 articles (03/2015 - 05/2012)|
|5.||Sharples, Gary J: 4 articles (01/2014 - 08/2005)|
|6.||Ma, Yan: 3 articles (03/2015 - 05/2012)|
|7.||Curtis, Fiona A: 3 articles (01/2014 - 08/2005)|
|8.||Reed, Patricia: 3 articles (01/2014 - 08/2005)|
|9.||Harris, Norman R: 3 articles (03/2011 - 04/2009)|
|10.||Carter, Patsy R: 3 articles (03/2011 - 04/2009)|
01/01/2014 - "We have developed a broad-range HIV-1 LTR specific recombinase that has the potential to be effective against the vast majority of HIV-1 strains and to cure HIV-1 infected cells from the infection. "
01/01/2014 - "To advance our Tre-based strategy towards a universally efficient cure, we have engineered a new, universal recombinase (uTre) applicable to the majority of HIV-1 infections by the various virus strains and subtypes. "
12/01/2013 - "We have recently established an expression platform in Sf9 cells using a fluorescence-based recombinase mediated cassette exchange (RMCE) strategy which has similar development timelines but avoids baculovirus infection. "
12/01/2012 - "The data clearly illustrate that although Xer1 recombinase is not a virulence factor of M. agalactiae and Vpma phase variation is not necessary for establishing an infection, it might critically influence the survival and persistence of the pathogen under natural field conditions, mainly due to a better capacity for dissemination and evoking systemic responses. "
02/01/2012 - "Use of recombinase-based in vivo expression technology to characterize Enterococcus faecalis gene expression during infection identifies in vivo-expressed antisense RNAs and implicates the protease Eep in pathogenesis."
05/01/2012 - "p53(FRT) mice will enable dual recombinase technology to study cancer biology because Cre is available to modify genes specifically in stromal cells to investigate their role in tumor development, progression and response to therapy."
12/01/2015 - "The 'off-target' activity of RAG recombinases contributes to mutations and cancer. "
09/01/2015 - "This application of dual recombinase technology can be used to dissect the role of stromal cells in tumor development and cancer therapy. "
08/01/2014 - "Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium."
12/01/2009 - "This review highlights the current techniques used to generate transgenic mouse models of cancer, with an emphasis on recent advances in the use of ubiquitous promoters, models that use Cre-loxP and Flip-FRT recombinase technology, inducible systems, RNAi to target genes, and transposon mutagenesis. "
07/01/2011 - "Studies further demonstrated that CD4(+) T cells induced bladder inflammation in URO-OVA mice depleted of CD8(+) T cells or deficient in the recombinase activating gene-1 (Rag-1(-/-)). "
04/01/2009 - "In this study, CD4+CD45RBhigh T cells obtained from healthy C57BL/6 donor mice were transferred into lymphopenic recombinase-activating gene-1-deficient (RAG knockout) mice, which induced small and large bowel inflammation. "
03/01/2011 - "Adoptive transfer of CD4(+) T cells obtained from interleukin-10-deficient (IL-10(-/-)) mice into lymphopenic recombinase-activating gene-1-deficient (RAG(-/-)) mice induces chronic colonic inflammation, with the inflammation ranging from mild to severe as determined by blinded histological analyses. "
08/15/2002 - "The adoptive transfer of CTLA-4-deficient splenocytes or Thy 1(+) cells into recombinase-activating gene 2-deficient mice resulted in fatal inflammation and tissue destruction similar to that seen in CTLA-4-deficient mice. "
05/01/1998 - "T and B cell-deficient, recombinase-activating-gene-deficient mice (RAG -/-) failed to develop significant allergic inflammation and AH following allergen challenge. "
|1.||nestin (nestin protein)
|4.||Type I DNA Topoisomerases (Topoisomerase I)
|7.||Interleukin-10 (Interleukin 10)
|10.||DNA (Deoxyribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Transplantation (Transplant Recipients)